Business Context and Reporting Period
Surrozen, Inc. filed a Form 8-K reporting a material financing arrangement entered into on February 18, 2022, with Lincoln Park Capital Fund, LLC. The filing was signed on February 24, 2022. Surrozen is a Delaware biotechnology company whose common stock and warrants trade on Nasdaq under SRZN and SRZNW, respectively.
Key Financial and Capital Markets Terms
| Item | Terms |
|---|---|
| Committed equity facility | Surrozen may sell newly issued common shares to Lincoln Park for aggregate proceeds of up to $50.0 million. |
| Company obligation | Surrozen is not required to sell any shares and controls the timing and amount of sales. |
| Initial issuance | 100,000 common shares were issued to Lincoln Park as consideration for its commitment. |
| Additional fee | Surrozen must pay Lincoln Park $100,000 if aggregate share purchases reach at least $30.0 million. |
| Purchase price | Regular purchases are priced using the lower of specified market-price measures. Accelerated purchases are priced at 96% of the lower of specified closing-price or volume-weighted-average-price measures. |
| Share limits | Regular purchases are generally limited to 30,000 shares, with potential increases to 35,000 or 40,000 shares at specified prices. Single regular purchases are capped at $3.5 million. Accelerated purchases are subject to formula-based limits, with a possible mutually agreed limit of 500,000 shares. |
| Exchange Cap | Issuances are generally limited to 7,003,383 shares, or 19.99% of shares outstanding before execution, unless stockholder approval is obtained or the average purchase price is at least $2.86 per share. |
| Ownership limitation | Lincoln Park may not beneficially own more than 9.99% of Surrozen’s outstanding common stock. |
| Use of proceeds | Working capital and general corporate purposes. |
The filing does not provide revenue, profit or loss, operating cash flow, cash balances, margins, debt balances, liquidity runway, or other periodic financial statement metrics.
Material Changes Versus the Prior Comparable Period
- The filing announces a new potential equity funding source of up to $50.0 million; it does not provide a prior-period comparison.
- Surrozen issued 100,000 shares to Lincoln Park in an unregistered transaction, resulting in immediate equity dilution.
- The company obtained flexibility to raise capital over multiple transactions for up to 36 months after the facility commences, subject to the agreement’s conditions and limits.
Outlook, Conditions, Risks, and Unusual Items
- Lincoln Park’s purchase obligation begins only after specified conditions are satisfied, including effectiveness of a resale registration statement and filing of a related prospectus.
- Surrozen agreed to file the resale registration statement by April 15, 2022 and maintain its effectiveness for the specified period.
- Lincoln Park is generally obligated to purchase shares only when the Nasdaq closing sale price is at least $1.00.
- The facility may terminate after Lincoln Park purchases $50.0 million of shares, upon specified bankruptcy events, or after the applicable 36-month period. Either party may terminate if commencement has not occurred by September 30, 2022, and Surrozen may terminate after commencement without an additional cost or penalty.
- The arrangement may create substantial future dilution, and the amount of capital raised depends on market prices, trading volume, and Surrozen’s decision to sell shares.
- Surrozen is prohibited from entering into certain variable-rate transactions with parties other than Lincoln Park during the facility, while Lincoln Park agreed not to engage in short sales or hedging transactions that establish a net short position in Surrozen stock.
- The 100,000 shares were issued without registration in reliance on Section 4(a)(2) and Rule 506(b) of Regulation D to an accredited investor.
Facts Investors Should Verify
- Whether the resale registration statement was filed by April 15, 2022 and declared effective.
- Whether Surrozen subsequently sold shares under the facility, the prices received, cumulative proceeds, and remaining availability.
- The number of shares outstanding after the initial issuance and any subsequent sales, including dilution relative to the Exchange Cap.
- Surrozen’s cash balance, operating cash burn, debt, liquidity runway, and use of proceeds in subsequent filings.
- Whether the $100,000 additional fee was triggered by aggregate purchases of at least $30.0 million.
- Any subsequent termination, amendment, stockholder approval, or Nasdaq compliance issues related to the facility.